MD PhD, Leading a group working on array-based protein analysis. Our goal is to make proteomics simple and accessible. In Microsphere Affinity Proteomics (MAP) biotinylated sample proteins are captured onto bead-based antibody arrays and detected by flow cytometry. MAP has a multiplexing capacity similar to that of mass spectrometry but the throughput is at least two orders of magnitude higher. We are currently developing a multiplexed version of the western blot and complete set of MAP assays to analyze proteins and protein complexes in subcellular compartments. We are also developing a MAP array with thousands of recombinant human proteins. The MAP protein array will be used to test the specificity of antibodies to human proteins and to screen for autoantibodies in serum from patients with auto-immune disease and cancer. To validate MAP, we make extensive use of mass spectrometry. We generate reference data sets that are as lookup tables to identify antibody targets that correspond to specific binding or cross-reactivity, respectively. MAP technology is a game changer in antibody validation and protein detection. Lund-Johansen and co-workers have published work on MAP technology published in Molecular&Cellular Proteomics (2009, 2016), Proteomics (2011), New Biotechnology (2012)and Cytometry (2012). More recently, the group has published new bioinformatics for subcellular proteomics (Nature Methods in press)